A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms

被引：0
|
作者：
Rambaldi, Alessandro [1 ]
Dellacasa, Chiara Maria [2 ]
Salmoiraghi, Silvia [2 ]
Spinelli, Orietta [2 ]
Ferrari, Maria Luisa [2 ]
Gattoni, Elisabetta [3 ]
Guglielmelli, Paola [4 ]
Vannucchi, Alessandro M. [4 ]
Barosi, Giovanni [5 ]
Barbui, Tiziano [2 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona, Spain
[2] Osped Riuniti Bergamo, USC Hematol, I-24100 Bergamo, Italy
[3] Policlin San Matteo, Fdn IRCCS, Lab Epidemiol Clin, I-27100 Pavia, Italy
[4] Univ Florence, Florence, Italy
[5] Ist Policlin San Matteo, Clin Epidemiol Unit, Ctr Study Myelofibrosis, Pavia, Italy
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [41] Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms
    Ueda, Koki
    Ikeda, Kazuhiko
    Ogawa, Kazuei
    Shichishima-Nakamura, Akiko
    Shide, Kotaro
    Shimoda, Kazuya
    Hashimoto, Yuko
    Mason, Philip J.
    Bessler, Monica
    Takeishi, Yasuchika
    BLOOD, 2015, 126 (23)
  • [42] Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome
    Abu-Zeinah, Ghaith
    Di Giandomenico, Silvana
    Choi, Daniel
    Cruz, Tatiana
    Erdos, Katie
    Taylor, Elwood, III
    Ritchie, Ellen K.
    Silver, Richard T.
    Scandura, Joseph M.
    BLOOD ADVANCES, 2022, 6 (18) : 5477 - 5481
  • [43] The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms
    Sahin, Ezgi
    Yonal-Hindilerden, Ipek
    Hindilerden, Fehmi
    Aday, Aynur
    Nalcaci, Meliha
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 150 - 165
  • [44] PEGIFN2A IN THE TREATMENT OF PH NEGATIVE JAK2V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS - CENTRE EXPERIENCE
    Gisela, Ferreira
    Margarida, Coucelo
    Maria Joao, Mendes
    Alexandra, Pereira
    Marta, Duarte
    Jose Carlos, Almeida
    Leticia, Ribeiro
    HAEMATOLOGICA, 2016, 101 : 183 - 183
  • [45] JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms
    Bagheropur S.
    Ehsanpour A.
    Birgani M.T.
    Saki N.
    memo - Magazine of European Medical Oncology, 2018, 11 (2) : 152 - 157
  • [46] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes, Raoul
    Mesa, Ruben A.
    LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
  • [47] Calreticulin Mutation in JAK2V617F Negative Myeloproliferative Neoplasms - The Beaumont Experience
    Sikdar, Soma
    Prada, Anne
    Crisan, Dominita
    LABORATORY INVESTIGATION, 2015, 95 : 378A - 378A
  • [48] Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
    De Moner, Blanca
    Martinez-Sanchez, Julia
    Garrote, Marta
    Ramos, Alex
    Ventosa-Capell, Helena
    Moreno-Castano, Ana
    Nomdedeu, Meritxell
    Ojeda, Asuncion
    Escolar, Gines
    Garcia-Pagan, Joan Carles
    Arellano-Rodrigo, Eduardo
    Carreras, Enric
    Alvarez-Larran, Alberto
    Diaz-Ricart, Maribel
    THROMBOSIS AND HAEMOSTASIS, 2025,
  • [49] Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
    Kaiyao Shi
    Wanke Zhao
    Yun Chen
    Wanting Tina Ho
    Ping Yang
    Zhizhuang Joe Zhao
    Journal of Hematology & Oncology, 7
  • [50] Enhanced Molecular Response in Myeloproliferative Neoplasms with Complete JAK2V617F Inhibition
    Celik, Hamza
    Challen, Grant A.
    CANCER DISCOVERY, 2024, 14 (05) : 701 - 703
12345